Recombinant Human DLEC/CLEC4C/BDCA-2 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human DLEC/CLEC4C/BDCA-2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to bind fluorescein-conjugated S. aureus Bioparticles. Jiang, Y. et al. (2006) J. Biol. Chem. 281:11834. The ED₅₀ for this effect is 0.5-2.5 µg/mL.
• Source: Mouse myeloma cell line, NS0-derived human DLEC/CLEC4C/BDCA-2 protein
  

  Human IgG1 (Ser102-Lys330)	IEGR	Human DLEC (Phe46-Ile213) Accession # Q8WTT0
  N-terminus		C-terminus

• Accession #: Q8WTT0
• N-terminal Sequence: Ser102 (Fc)
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 46 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 55-61 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human DLEC/CLEC4C/BDCA-2 Fc Chimera Protein, CF

• BDCA2
• BDCA-2
• BDCA2MGC125791
• blood dendritic cell antigen 2 protein
• Blood dendritic cell antigen 2
• CD303 antigen
• CD303
• CLEC4C
• CLECSF11
• CLECSF11PRO34150
• CLECSF7
• C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 11
• C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 7
• C-type lectin domain family 4 member C
• C-type lectin superfamily member 7
• dendritic cell lectin b
• Dendritic lectin
• DLEC
• DLECMGC125792
• HECL
• HECLMGC125793
• MGC125789
• PRO34150

Background

Dendritic cell lectin (DLEC), also known as BDCA-2, CD303, HECL, and CLEC4C/CLECSF11/CLECSF7, is a 38 kDa type II transmembrane protein in the C-type lectin family (1). Mature human DLEC consists of a 21 amino acid (aa) cytoplasmic domain, a 23 aa transmembrane segment, and a 169 aa extracellular domain (ECD) that contains a juxtamembrane neck region and one carbohydrate recognition domain (CRD) (2, 3). Alternate splicing may generate multiple isoforms that lack the transmembrane segment and/or portions of the cytoplasmic, neck, and CRD regions (2 - 4). An ortholog of human DLEC has not been described in mouse or rat. DLEC expression is restricted to plasmacytoid dendritic cells (pDC) and is downregulated during their maturation (2, 3, 5). pDC play a role in the innate immune response by producing IFN-alpha / beta following exposure to TLR7 and TLR9 agonists such as microbial CpG DNA (3, 5 - 8). Antibody ligation of DLEC on pDC attenuates the CpG-stimulated production of interferons as well as a Th1 biased response (3, 5 - 9). DLEC interactions with HIV-1 gp120 and hepatitis B virus soluble antigen may therefore limit the pDC antiviral response (10, 11). Similar to other C-type lectins, DLEC can mediate antigen uptake for MHC loading and presentation to T cells (3, 12). Crosslinking of DLEC on CpG-stimulated pDC inhibits pDC maturation and induces tyrosine phosphorylation on multiple proteins involved in B cell receptor signaling and endocytosis (5, 7, 8). These functions require the association of DLEC with the ITAM-containing Fc epsilon RI gamma chain (7, 8).

1. Kanazawa, N. et al. (2004) Immunobiology 209:179.
2. Arce, I. et al. (2001) Eur. J. Immunol. 31:2733.
3. Dzionek, A. et al. (2001) J. Exp. Med. 194:1823.
4. Fernandes, M.J. et al. (2000) Genomics 69:263.
5. Wu, P. et al. (2008) Clin. Immunol. 129:40.
6. Fanning, S.L. et al. (2006) J. Immunol. 177:5829.
7. Rock, J. et al. (2007) Eur. J. Immunol. 37:3564.
8. Cao, W. et al. (2007) PloS Biol. 5:e248.
9. Riboldi, E. et al. (2009) Immunobiology 214:868.
10. Martinelli, E. et al. (2007) Proc. Natl. Acad. Sci. 104:3396.
11. Xu, Y. et al. (2009) Mol. Immunol. 46:2640.
12. Jaehn, P.S. et al. (2008) Eur. J. Immunol. 38:1822.

Bioinformatics

• Uniprot:
  • Q8WTT0()